Delving into the Latest Updates on Jiangsu Yew Health Technology Co., Ltd. with Synapse

Overview

主要目的：考察中国健康男性受试者在空腹/餐后条件下单次口服由无锡紫杉药业股份有限公司持有，上海创诺制药有限公司生产的阿帕他胺片（规格：60mg）与Janssen-Cilag International NV持证的阿帕他胺片（商品名：Erleada®/安森珂®，规格：60mg）后的体内药代动力学特征，评价两制剂的生物等效性。次要目的：评价单剂量口服阿帕他胺片受试制剂及参比制剂在中国健康男性受试者中的安全性。

[Translation]

Primary objective: To investigate the in vivo pharmacokinetic characteristics of apalutamide tablets (specification: 60 mg) owned by Wuxi Taxus Pharmaceutical Co., Ltd. and produced by Shanghai Chuangnuo Pharmaceutical Co., Ltd. and apalutamide tablets (trade name: Erleada®/Ansenke®, specification: 60 mg) licensed by Janssen-Cilag International NV in healthy Chinese male subjects after a single oral administration under fasting/postprandial conditions, and to evaluate the bioequivalence of the two preparations. Secondary objective: To evaluate the safety of the test and reference preparations of apalutamide tablets after a single oral dose in healthy Chinese male subjects.

Start Date14 Feb 2025

Sponsor / Collaborator

Wuxi Taxus Pharmaceutical Co Ltd.

100 Clinical Results associated with Jiangsu Yew Health Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Jiangsu Yew Health Technology Co., Ltd.

Login to view more data

100 Deals associated with Jiangsu Yew Health Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Jiangsu Yew Health Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data